ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD 3.780
+0.220 (6.18%)
Jun 18, 2026, 2:14 PM HKT
HKG:1541 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -218.58 | -315.86 | -379.46 | -402.89 | -732.95 |
Depreciation & Amortization | 14.61 | 20.68 | 22.58 | 17.62 | 13.18 |
Loss (Gain) From Sale of Assets | - | - | - | - | -0.56 |
Asset Writedown & Restructuring Costs | - | 27.4 | - | - | - |
Loss (Gain) From Sale of Investments | -0.06 | -14.15 | -1.76 | - | -1.6 |
Stock-Based Compensation | 15.77 | 34.21 | 71.64 | 103.83 | 34.02 |
Other Operating Activities | 5.38 | -5.45 | -5.24 | 20.69 | 521.45 |
Change in Accounts Receivable | 0.02 | 0.02 | 0.03 | -0.03 | 0.01 |
Change in Accounts Payable | -19.63 | 27.57 | 6.36 | 4.88 | 7.65 |
Change in Unearned Revenue | -7.65 | 32.9 | - | - | - |
Change in Other Net Operating Assets | 7.56 | 64.64 | -81.71 | 17.21 | -31.74 |
Operating Cash Flow | -202.58 | -128.04 | -367.55 | -238.71 | -190.54 |
Capital Expenditures | -1.31 | -10.4 | -2.69 | -23.22 | -40.7 |
Sale of Property, Plant & Equipment | - | - | - | - | 0.58 |
Investment in Securities | -61.88 | 40.72 | -303.37 | - | 23.65 |
Other Investing Activities | 72.92 | 7.63 | 11.21 | 23.27 | -92.25 |
Investing Cash Flow | 9.73 | 37.95 | -294.85 | 0.05 | -108.72 |
Short-Term Debt Issued | - | - | - | - | 0.01 |
Long-Term Debt Issued | 251.96 | 175.78 | 79.96 | - | - |
Total Debt Issued | 251.96 | 175.78 | 79.96 | - | 0.01 |
Short-Term Debt Repaid | - | - | - | - | -0.01 |
Long-Term Debt Repaid | -159.78 | -125.8 | -26.21 | -5.8 | -4.77 |
Total Debt Repaid | -159.78 | -125.8 | -26.21 | -5.8 | -4.78 |
Net Debt Issued (Repaid) | 92.18 | 49.98 | 53.76 | -5.8 | -4.77 |
Issuance of Common Stock | 320.35 | 215.94 | 307.79 | 189.57 | 800.98 |
Other Financing Activities | -10.18 | -6.99 | -30.51 | -4.39 | -3.17 |
Financing Cash Flow | 402.36 | 258.93 | 331.04 | 179.38 | 793.03 |
Foreign Exchange Rate Adjustments | -7.54 | 1.79 | 3.14 | 26.17 | -9.12 |
Miscellaneous Cash Flow Adjustments | - | -0.01 | - | - | - |
Net Cash Flow | 201.96 | 170.62 | -328.23 | -33.11 | 484.65 |
Free Cash Flow | -203.9 | -138.44 | -370.25 | -261.93 | -231.24 |
Free Cash Flow Margin | -132.15% | -186.70% | -4811.50% | -4603.41% | -1674.69% |
Free Cash Flow Per Share | -0.49 | -0.37 | -1.02 | -0.79 | -2.68 |
Cash Interest Paid | 5.3 | 3.45 | 1.52 | 0.79 | 0.89 |
Levered Free Cash Flow | -65.6 | -135.44 | -193.42 | -2,538 | - |
Unlevered Free Cash Flow | -62.28 | -133.29 | -192.47 | -2,537 | - |
Change in Working Capital | -19.7 | 125.13 | -75.32 | 22.05 | -24.08 |